自身免疫性肝炎急性表现的患病率与结局:系统综述与荟萃分析
该系统综述与荟萃分析检索多个数据库至2025年7月,纳入报告自身免疫性肝炎(AIH)急性表现的观察性研究。结果显示,39%的AIH患者以急性表现起病,不同急性亚型的患病率及无移植生存率差异显著,进展至急性肝衰竭者结局较差。
要点
- 约39%的AIH患者以急性表现起病,亚型包括非重型、重型、ALF及ACLF等。
- 急性重型AIH的90天无移植生存率为79%,而AIH相关ALF仅19%。
- 多数急性非重型及急性重型患者经及时治疗可获得较好结局。
核心结论
- 急性表现是AIH的常见起病形式,各亚型临床轨迹差异显著。
- 多数急性非重型、急性/重型加重及急性重型AIH患者经及时治疗可获得较好无移植生存。
- 进展至急性肝衰竭者无移植生存率差。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase、Web of Science、Scopus和Cochrane Library自建库至2025年7月。
- 采用随机效应模型生成合并患病率和无移植生存率估计,并使用JBI清单评估研究质量。
主要发现
- 在10项同时报告总AIH队列和急性表现的研究中,AIH患者急性起病的合并比例为39%(95%CI 27%-54.0%;I2=95%)。
- 急性非重型AIH的合并患病率为21%(95%CI 14%-30%;I2=75.6%),急性重型AIH为15.0%(95%CI 9%-23%;I2=79.4%)。
- AIH相关ALF的合并患病率为3%(95%CI 1%-9%;I2=90.1%),慢性AIH急性/重型加重为15%(95%CI 9%-25%;I2=91.8%),AIH相关ACLF为11%(95%CI 7%-16%;I2=78.5%)。
- 急性重型AIH的合并90天无移植生存率为79%(95%CI 36%-96%;I2=0%),AIH相关ALF为19%(95%CI 11%-31%;I2=0%)。
- 多数表型间异质性仍显著。
临床怎么用
- 临床遇到急性起病的AIH患者应识别其具体急性表型以评估预后。
- 对急性重型AIH及进展至ALF者需及时治疗并考虑移植评估。
局限性
- 多数表型间异质性显著(I2较高)。
- 部分分析中90天无移植生存率估计的置信区间较宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Acute presentations of autoimmune hepatitis (AIH) ranging from acute hepatitis to acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) are diagnostically challenging and clinically heterogeneous. We performed a systematic review and meta-analysis to determine the prevalence of acute AIH presentations and to evaluate transplant-free survival (TFS) across subtypes. METHODS: We searched PubMed, Embase, Web of Science, Scopus, and the Cochrane Library from inception through July 2025 for observational studies reporting acute AIH presentations. Random-effects models generated pooled prevalence and TFS estimates, with a general/unselected-cohort sensitivity analysis performed where feasible. Study quality was assessed using the JBI checklist. RESULTS: Across 10 studies reporting both a total AIH cohort size and a separately quantified acute presentation, the pooled proportion of AIH patients presenting acutely was 39% (95% CI 27%-54.0%; I2=95%). Thirty-four studies were included to describe different acute phenotypes. The pooled prevalence of acute non-severe AIH (ANS-AIH), acute severe AIH (AS-AIH), AIH-associated ALF, acute/severe exacerbation of chronic AIH, and AIH-associated ACLF was 21% (95% CI, 14%-30%; I2=75.6%), 15.0% (95% CI, 9%-23%; I2=79.4%), 3% (95% CI, 1%-9%; I2=90.1%), 15% (95% CI, 9%-25%; I2=91.8%), and 11% (95% CI, 7%-16%; I2=78.5%), respectively. TFS was standardized to 90-day timepoint where feasible. Pooled 90-day TFS was 79% (95% CI 36-96%; I2=0%) for AS-AIH and 19% (11%-31%; I2=0%) for AIH-ALF. Heterogeneity remained substantial across most phenotypes. CONCLUSIONS: Acute presentations are common in AIH and span phenotypes with profoundly different clinical trajectories. While most patients with ANS-AIH, acute/severe exacerbations and AS-AIH achieve favorable outcomes with timely therapy, progression to ALF carries poor TFS.
引用
- Taneja S, Aravind N, Mehtani R, et al. Prevalence and outcomes of acute presentations of autoimmune hepatitis: Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2026. PMID: 42946107. doi:10.1016/j.cgh.2026.10.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。